Cell therapy for patients
OwnerDemao Yanginventor
Life of this patent
Estimating the term…
Abstract
Materials and methods of treating a patient with type 2 diabetes mellitus, metabolic syndrome, obesity, infertility, high blood pressure, hyperthyroidism, and hypothyroidism, hyperlipidaemia, osteoporosis, osteoarthritis, hypoadrenalism, polycystic ovary syndrome, or Parkinson's disease comprising administering a therapeutically effective amount of ex vivo cultured activated peripheral blood mononuclear cells (PBMCs) to the patient. The ex vivo cultured activated cells are activated and cultured in a presence of a cytokine and may be autologous or allogeneic relative to the patient.
Claims6
A method of treating a patient with osteoporosis, osteoarthritis, polycystic ovary syndrome, or Parkinson's disease, comprising administering a therapeutically effective amount of ex vivo cultured activated peripheral blood mononuclear cells (PBMCs) to a patient with osteoporosis, osteoarthritis, polycystic ovary syndrome, or Parkinson's disease wherein the ex vivo cultured activated cells are autologous to the patient and are activated and cultured in a presence of a cytokine, wherein the cytokine comprises a combination of Interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF);
- wherein a dose of the ex vivo cultured activated PBMCs ranges from 1×105 to 2×108 cells, and the method further comprising administering 2-20 of the doses of vivo cultured activated PBMCs over a period of time ranging from 1-26 weeks.
Dependencies are inferred from the claim text.